Kura Oncology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kura Oncology Inc (KURA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Kura Oncology Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 77M vs 39,006M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.1% annualized vs trailing 12 months), vs accelerating (+9.8%) for its tracked peer group.
- Growth: Kura Oncology Inc generated 36.5% revenue growth year over year in Q2 2026, vs 21.9% for its tracked competitors combined.
- Profitability: Its -327.3% net margin compares with 15.0% for the peer group.
- Scale: Kura Oncology Inc ranks #153 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Kura Oncology Inc accounted for 0.2% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.30M compares with $1.33M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
KURA Sales vs. its Competitors, Q2 2026
Kura Oncology Inc reported revenue growth of 36.54 % year on year in Q2 2026, above its competitors' combined revenue growth of 21.94 %.
With a net margin of -327.33 %, Kura Oncology Inc reported lower profitability than its competitors (15.01 %).
Kura Oncology Inc generated 0.19 % of the combined sales of its peer group, up from 0.17 % a year earlier.
Kura Oncology Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Kura Oncology Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Kura Oncology Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Kura Oncology Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 36.5% for Kura Oncology Inc. Kura Oncology Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Kura Oncology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kura Oncology Inc | No | - | - | Yes |
| Competitors combined (61) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KURA Stock Performance relative to its Competitors
KURA Stock Performance relative to High-Confidence Competitors
KURA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 3 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 4 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 5 | Enliven Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kura Oncology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Kura Oncology Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Kura Oncology Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Kura Oncology Inc | 932.09 | 77.23 |
| Vertex Pharmaceuticals Inc | 134,619.28 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 80,401.00 | 15,534.70 |
| Alnylam Pharmaceuticals Inc | 34,741.03 | 4,804.18 |
| Zai Lab Limited | 28,750.89 | 449.61 |
| Madrigal Pharmaceuticals Inc | 14,772.03 | 1,283.94 |
| SUBTOTAL | 398,187.29 | 40,414.36 |
Sign in to see all competitors of Kura Oncology Inc .
Sources: Kura Oncology Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kura Oncology Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kura Oncology Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicara Therapeutics Inc | Named by the company | 85% |
| BMS | Named by the company | 85% |
| Mirati | Named by the company | 85% |
| Allarity Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Kura Oncology Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Kura Oncology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kura Oncology Inc | 932 | 297,019 | -1,141,442 |
| Vertex Pharmaceuticals Inc | 134,619 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 80,401 | 1,008,092 | 280,902 |
| Alnylam Pharmaceuticals Inc | 34,741 | 1,921,673 | 323,195 |
| Zai Lab Limited | 28,751 | 252,026 | -105,501 |
| Madrigal Pharmaceuticals Inc | 14,772 | 1,403,213 | -355,295 |
| PEERS TOTAL | 397,255 | 1,328,978 | 145,717 |
Sign in to see all peers for Kura Oncology Inc .
Kura Oncology Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Kura Oncology Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Protagonist Therapeutics inc | Single reportable segment 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Kura Oncology Inc .
Kura Oncology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Kura Oncology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Kura Oncology Inc ranks #153 of 498 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 153 | Kura Oncology Inc | 932 | 0.02 % |
Market cap and industry share for the rest of Kura Oncology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Kura Oncology Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 148 | Pacira Biosciences inc | 1,024 | -0.96 % |
| 149 | Janux Therapeutics Inc | 1,021 | -25.47 % |
| 150 | Mannkind Corporation | 1,016 | -38.37 % |
| 151 | Arbutus Biopharma Corp | 956 | 12.04 % |
| 152 | Rigel Pharmaceuticals Inc | 1,234 | 12.3% |
| 153 | Kura Oncology Inc | 932 | 25.48 % |
| 154 | Olema Pharmaceuticals Inc | 1,234 | 12.3% |
| 155 | Alumis inc | 1,234 | 12.3% |
| 156 | Moonlake Immunotherapeutics | 1,234 | 12.3% |
| 157 | Cypherpunk Technologies Inc | 1,234 | 12.3% |
| 158 | Theravance Biopharma inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Kura Oncology Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Kura Oncology Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 99.35 % | 64.89 % (avg) | +34.5 pp |
| Operating Margin | -411.90 % | industry median | -358.2 pp |
| EBITDA Margin | -404.95 % | -7.21 % (avg) | -397.7 pp |
| Capital Intensity (Capex / Revenue) | 7.34 % | 4.92 % (avg) | +2.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Kura Oncology Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 6.2x | 4.5x | +1.7x |
| Return on Equity | -207.18 % | industry aggregate | -224.43 % |
| Return on Invested Capital | -45.73 % | -2.95 % (avg) | -42.78 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kura Oncology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | -449.94 % |
| Return on Invested Capital | -26.10 % | -15.62 % | -12.55 % | -11.95 % | -15.73 % | -19.39 % | -19.63 % | -34.71 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Kura Oncology Inc's BCG Growth-Share Matrix
Relative market share (vs Kura Oncology Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) — a common framework, not a precision instrument.
Kura Oncology Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Kura Oncology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 7.34 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Kura Oncology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Kura Oncology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Kura Oncology Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Kura Oncology Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Kura Oncology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+8.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 358.2 points below the industry median.
- Return on equity 224.4 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (41.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Kura Oncology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kura Oncology Inc | 0.77 | 5.49 | 0.07 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Alnylam Pharmaceuticals Inc | 1.12 | 2.86 | 1.18 |
| Zai Lab Limited | 1.66 | 2.45 | 0.31 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
Sign in to see all peers for Kura Oncology Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kura Oncology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kura Oncology Inc | Q2 2026 | +36.5 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +66.9 % | - |
| Zai Lab Limited | Q2 2026 | -3.3 % | - |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| PEERS TOTAL | +24.1 % | +88.0 % |
Sign in to see all peers for Kura Oncology Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kura Oncology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kura Oncology Inc | Q2 2026 | - | -55.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +110.0 % | +142.6 % |
| Zai Lab Limited | Q2 2026 | +12.0 % | -53.5 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
Sign in to see all peers for Kura Oncology Inc .
Kura Oncology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kura Oncology Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Alnylam Pharmaceuticals Inc | 15.76% | 22.10% | 93.61% |
| Zai Lab Limited | - | - | - |
| Madrigal Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Kura Oncology Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kura Oncology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kura Oncology Inc | - | 12.07 |
| Vertex Pharmaceuticals Inc | 30.76 | 10.69 |
| Regeneron Pharmaceuticals Inc | 18.78 | 5.18 |
| Alnylam Pharmaceuticals Inc | 44.47 | 7.23 |
| Zai Lab Limited | - | 63.95 |
| Madrigal Pharmaceuticals Inc | - | 11.51 |
| PEERS AVERAGE | 96.51 | 9.85 |
Sign in to see all peers for Kura Oncology Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.